What the FDA labels say about taking them together
Cobicistat and ticagrelor
Cobicistat's FDA label of February 10, 2026 names ticagrelor in its drug interactions section; the ticagrelor label PlainMeds reads does not name cobicistat. The cobicistat label: “Coadministration with ticagrelor is not recommended.”
Check it at the source: the cobicistat FDA label on DailyMed (effective February 10, 2026, Gilead Sciences, Inc.); the ticagrelor FDA label on DailyMed (effective May 7, 2026, AstraZeneca Pharmaceuticals LP).
What does the cobicistat label say about ticagrelor?
Cobicistat label, drug interactionsConcomitant Drug Class/Drug Name: ticagrelor; Potential Effect ↑ = Increase, ↓ = Decrease, ↔ = No change: ↑ ticagrelor; Clinical Comment: Coadministration with ticagrelor is not recommended.
Source: FDA drug label (Tybost), Gilead Sciences, Inc., effective February 10, 2026 (SPL set 3784c35c-e87f-410c-900b-8fd6313c6010), via openFDA; the full label on DailyMed
What does the ticagrelor label say about cobicistat?
Ticagrelor's label (effective May 7, 2026) does not name cobicistat in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (BRILINTA), AstraZeneca Pharmaceuticals LP, effective May 7, 2026 (SPL set f7b3f443-e83d-4bf2-0e96-023448fed9a8), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Cobicistat | Ticagrelor | |
|---|---|---|
| Labeled for | HIV | Heart attack and coronary artery disease, Stroke prevention |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | n/a | $0.253 per tablet 90 mg tablet |
| Shortage now | A presentation being discontinued | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once